ReviewAlzheimer's research & therapy2016
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.
Review in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03094975 (A Multicenter Registry Study of Aneurysmal Subarachnoid Hemorrhage), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Registry Study of Aneurysmal Subarachnoid Hemorrhage
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort.Journal of Alzheimer's disease : JAD · 2021Article
- Leveraging neuropathological data in pharmacoepidemiology: A promising approach for dementia prevention?Pharmacoepidemiology and drug safety · 2021Article
- Do Patient Concerns About Antihypertensive Use For Dementia Prevention Vary By Current Use Of Antihypertensive?Patient preference and adherence · 2019Article
- Article
- The association between blood pressure variability (BPV) with dementia and cognitive function: a systematic review and meta-analysis protocol.Systematic reviews · 2018Article
- The application of PRECIS-2 ratings in randomized controlled trials of Chinese herbal medicine.Oncotarget · 2017Article
- Multiple neuropathologies and dementia in the aging brain: a key role for cerebrovascular disease?Alzheimer's & dementia (New York, N. Y.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 3 countries.
Funding
Abstract
Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the choice of treatments for other medical conditions. Despite the importance of these questions, very little research is available. The Alzheimer's Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the clinical care of common chronic diseases may protect from cognitive decline and dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.